Synthetic Biologics (SYN) Scheduled to Post Earnings on Thursday

Synthetic Biologics (NYSEAMERICAN:SYN) will post its Q3 quarterly earnings results after the market closes on Thursday, November 8th. Analysts expect Synthetic Biologics to post earnings of ($1.32) per share for the quarter.

Synthetic Biologics (NYSEAMERICAN:SYN) last released its earnings results on Wednesday, August 8th. The company reported ($1.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.40) by $0.35.

SYN stock opened at $0.91 on Tuesday. Synthetic Biologics has a 52 week low of $0.77 and a 52 week high of $27.65.

A number of equities research analysts have recently weighed in on SYN shares. Zacks Investment Research lowered shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Synthetic Biologics in a research report on Thursday, August 9th.

COPYRIGHT VIOLATION WARNING: “Synthetic Biologics (SYN) Scheduled to Post Earnings on Thursday” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at

About Synthetic Biologics

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Read More: What does the Dow Jones Industrial Average (DJIA) measure?

Earnings History for Synthetic Biologics (NYSEAMERICAN:SYN)

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.

Leave a Reply